Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Ovarian Neoplasms Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

9 recruiting trials for Ovarian Neoplasms. Eligibility criteria explained in plain English.

TrialFinderData lists 9 Ovarian Neoplasms clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 50% (2 studies); the largest phase groups are Phase 2: 2, Phase 1 / Phase 2: 1, Phase 1: 1.

Research is led by A2 Biotherapeutics Inc. (2), Cleo Diagnostics Ltd (1), McGill University (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Apheresis (other, 1 trial), followed by Next Generation Sequencing (NGS), Long Range NGS HLA typing.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
9
Total Trials
9
Recruiting Now
0
Phase 3 Trials
8
Sponsors

Track Ovarian Neoplasms trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT04981119

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect...

Sponsor: A2 Biotherapeutics Inc.Enrolling: 20016 locations
RECRUITINGNCT06566716

A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass

Ovarian cancer is a serious health risk with the highest death rate among gynecological cancers. Unfortunately, it's only possible to definitively diagnose ovarian cancer after...

Sponsor: Cleo Diagnostics LtdEnrolling: 10008 locations
RECRUITINGNCT02288676

DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics

This study aims to develop and validate a test for detecting ovarian and endometrial cancers early. It relies on detecting somatic mutations that are associated with these cancers...

Sponsor: McGill UniversityEnrolling: 12001 location
RECRUITINGPhase 2NCT04641247

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior...

This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently...

Sponsor: GlaxoSmithKlineEnrolling: 3720 locations
RECRUITINGPhase 2NCT04519151

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) for the treatment of platinum sensitive recurrent ovarian cancer. Participants will...

Sponsor: Sheba Medical CenterEnrolling: 241 location
RECRUITINGNCT06883409

Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer

This is a study that aims to demonstrate the non-inferiority of minimally invasive surgery versus open surgery, as an approach for patients with advanced ovarian cancer who...

Sponsor: Instituto Nacional de Cancerologia de MexicoEnrolling: 331 location
RECRUITINGNCT07280312

Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions

This clinical trial studies how well ultrasound microvessel imaging (UMI) works in evaluating ovarian and adnexal lesions in patients who are scheduled to have surgical treatment...

Sponsor: Mayo ClinicEnrolling: 401 location
RECRUITINGPhase 1 / Phase 2NCT06051695

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid...

The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC),...

Sponsor: A2 Biotherapeutics Inc.Enrolling: 47412 locations
RECRUITINGPhase 1NCT06885697

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors...

Background: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs. Mesothelin...

Sponsor: National Cancer Institute (NCI)Enrolling: 1001 location

Frequently Asked Questions

There are currently 9 clinical trials for Ovarian Neoplasms, with 9 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Ovarian Neoplasms, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Ovarian Neoplasms, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.